Fusion Pharmaceuticals Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 33.67 million compared to USD 24.29 million a year ago. Basic loss per share from continuing operations was USD 0.4 compared to USD 0.45 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.52 USD | +0.23% | +0.19% | +123.93% |
May. 31 | Fusion Pharmaceuticals Gets Court Order Approving AstraZeneca Deal | MT |
May. 29 | Fusion Pharmaceuticals Shareholders Approve AstraZeneca Deal | MT |
EPS Revisions
- Stock Market
- Equities
- FUSN Stock
- News FUSN PHAR
- Fusion Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024